Robin M Daly, Nicole Petrass, Shona Bass, and Caryl A Nowson

Size: px
Start display at page:

Download "Robin M Daly, Nicole Petrass, Shona Bass, and Caryl A Nowson"

Transcription

1 The skeletal benefits of calcium- and vitamin D 3 fortified milk are sustained in older men after withdrawal of supplementation: an 18-mo follow-up study 1 3 Robin M Daly, Nicole Petrass, Shona Bass, and Caryl A Nowson ABSTRACT Background: In a previous 2-y randomized controlled trial, we showed that calcium- and vitamin D 3 fortified milk stopped or slowed bone loss at several clinically relevant skeletal sites in older men. Objective: The present study aimed to determine whether the skeletal benefits of the fortified milk were sustained after withdrawal of the supplementation. Design: One hundred nine men 50 y old who had completed a 2-y fortified milk trial were followed for an additional 18 mo, during which no fortified milk was provided. Bone mineral density (BMD) of the total hip, femoral neck, lumbar spine, and forearm was measured by using dual-energy X-ray absorptiometry. Results: Comparison of the mean changes from baseline between the groups (adjusted for baseline age, BMD, total calcium intake, and change in weight) showed that the net beneficial effects of fortified milk on femoral neck and ultradistal radius BMD at the end of the intervention (1.8% and %, respectively; P 0.01 for both) were sustained at 18-mo follow-up (P 0.05 for both). The nonsignificant between-group differences at the total hip (0.8%; P 0.17) also persisted at follow-up (0.7%; P 0.10), but there were no lasting benefits at the lumbar spine. The average total dietary calcium intake in the milk supplementation group at follow-up approximated recommended amounts for Australian men 50 y old (1000 mg/d) but did not differ significantly from that in the control subjects (1021 versus 890 mg/d). Conclusion: Supplementation with calcium- and vitamin D 3 fortified milk for 2 y may provide some sustained benefits for BMD in older men after withdrawal of supplementation. Am J Clin Nutr 2008;87: KEY WORDS Milk supplementation, fortified milk, supplement withdrawal, men, bone mineral density, osteoporosis INTRODUCTION Increasing or maintaining adequate intakes of dietary calcium and vitamin D is recognized as an important strategy for the prevention and management of osteoporosis. In both elderly men and women, numerous randomized controlled trials (RCTs) have shown that the combined use of calcium and vitamin D supplements can reduce secondary hyperparathyroidism, slow the rate of bone turnover, and attenuate or even prevent age-related bone loss (1 3). The greatest benefits of supplementation are generally observed in persons who adhere to the supplementation regimen (4) or who have low dietary calcium intakes, low circulating concentrations of serum 25-hydroxyvitamin D [25(OH)D], or both (5 7). In a recent 2-y RCT in men 50 y old, we found that daily supplementation with 400 ml low-fat, calcium- and vitamin D 3 enriched milk containing 1000 mg Ca and 800 IU vitamin D 3 was effective for increasing serum 25(OH)D, reducing parathyroid hormone (PTH) concentrations, and stopping or slowing the rate of bone loss at the femoral neck, total hip, and ultradistal radius (8). Whereas these findings support the use of a food-based approach to increase dietary calcium and vitamin D intakes to help maintain bone status or prevent age-related bone loss in older men, an important clinical question that remains to be answered is whether there are any residual skeletal benefits after withdrawal of supplementation. Numerous follow-up studies have investigated the residual effects of supplementation with calcium, vitamin D, or both or of milk supplementation on BMD in older adults, but the findings have been inconsistent and predominantly limited to older women (9 11). Therefore, the aim of the present study was to determine whether the skeletal benefits obtained after supplementation with calcium- and vitamin D 3 fortified milk were sustained 18 mo after withdrawal of the supplementation in ambulatory community-dwelling men 50 y old. We hypothesized that the rates of change in BMD would not differ significantly between the milk supplementation and control groups during the follow-up period. SUBJECTS AND METHODS Study design and subjects This study was an 18-mo follow-up to a 2-y RCT designed to assess the effects of calcium- and vitamin D 3 fortified milk on 1 From the Centre for Physical Activity and Nutrition Research, School of Exercise and Nutrition Sciences, Deakin University, Melbourne, Australia. 2 Supported by grants from the Geoffrey Gardiner Dairy Foundation and the Helen M Schutt Trust and by a National Health and Medical Research Council Career Development Award (to RMD and SB). 3 Reprints not available. Address correspondence to RM Daly, Centre for Physical Activity and Nutrition Research, School of Exercise and Nutrition Sciences, Deakin University, 221 Burwood Highway, Burwood, Melbourne, Australia robin.daly@deakin.edu.au. Received July 3, Accepted for publication September 28, Am J Clin Nutr 2008;87: Printed in USA American Society for Nutrition 771

2 772 DALY ET AL BMD in middle-aged and older men. In the initial 2-y intervention (8), 167 men aged 50y(x SD age: y) were randomly allocated to either a calcium- and vitamin D 3 fortified milk group (milk supplementation group; n 85) or a usual-care control group (n 83). Men assigned to the fortified milk group were asked to consume daily 400 ml reduced-fat ( 1% fat) ultra-high-temperature (UHT) milk that contained 1000 mg Ca and 800 IU vitamin D 3. All participants enrolled in this study were healthy, ambulatory, community-dwelling white men who had a total hip, femoral neck, or lumbar spine BMD z score within 2 SDs. Participants were initially excluded if they had taken supplements of calcium ( 200 mg/d), vitamin D ( 200 IU/d), or both in the preceding 12 mo; had participated in regular highintensity resistance training in the previous 6 mo or participated in 150 min/wk of moderate- to high-impact weight-bearing exercise in the previous 6 mo; had a BMI 35; were lactose intolerant; consumed 4 alcoholic beverages/d; or had a history of osteoporotic fracture or medical disease or of the use of any medication known to affect bone metabolism. Of the 149 men who completed the original 2-y intervention, 109 (73%) completed the 18-mo follow-up evaluation: 55 (72%) from the milk supplementation group and 54 (74%) from the control group. The reasons for not attending the follow-up visit in the milk supplementation group were that the subject was not interested (n 12), had been diagnosed with cancer (n 2), could not be contacted (n 4), had moved away (n 2), or had died (n 1). For the control group, the main reasons were that the subject was not interested (n 13), had been diagnosed with cancer (n 2), could not be contacted (n 2), or had moved away (n 2). During the follow-up period, participants were not provided with the fortified milk, and they were not asked to avoid taking supplements that might have an affect on bone metabolism. At the completion of the 2-y intervention, all participants were informed of the results of the study and provided with a booklet outlining their individual results, including their changes in BMD. At baseline and at 24 mo, there were no significant differences in the subject characteristics (ie, age, anthropometry, diet, physical activity, or baseline BMD) between the men who did (n 109) and did not (n 58) attend the final follow-up visit. Written informed consent was obtained from all participants. The study was approved by the Deakin University Human Research Ethics Committee. Measurements To minimize the potential effects of seasonal variations on the key outcome measures, all testing for each data collection for both groups was completed within a 3-mo period, starting between April and June (which, in Australia, is from autumn to winter). Femoral neck, total hip, lumbar spine (L 2 L 4 ), ultradistal radius, and 33% radius BMD measurements were assessed by using dual-energy X-ray absorptiometry (DPX-L; Lunar Corp, Madison, WI) with DPX-L analysis software (version 4.7e; Lunar Corp). Patients were positioned for each scan according to standard procedures, and all follow-up scans were analyzed by using the manufacturer s scan-comparison mode. The short-term CV for repeated measurement in our laboratory ranged from 0.9% to 1.9% for the BMD measures. Quality control over the 42-mo study period was monitored by using the manufacturer s external spine phantom (CV: 0.65%). As described previously (8), height (in cm) was measured by using a stadiometer (Holtain Ltd, Crosswell, United Kingdom). Body weight (in kg) was assessed by using electronic scales that were correct to the nearest 0.1 kg (Seca GmbH, Hamburg, Germany). Body mass index (BMI; in kg/m 2 ) was calculated. At each visit, nutrient intakes were estimated from 3-d (2 weekdays and 1 weekend day) measured food diaries, with the option of weighing items, and intakes were analyzed by using FOOD- WORKS nutrient analysis software (version 4.0; Xyris Software, Brisbane, Australia). The Community Health Activities Model Program for Seniors physical activity survey (developed by the Institute for Health & Aging, University of California, San Francisco, and the Stanford Center for Research in Disease Prevention, Stanford University) was used to assess participation in recreational and organized physical activity (h weight-bearing exercise/wk) throughout the study (12). Information on the use of medication and supplements including calcium, vitamin D, and multivitamin supplementation and on alcohol consumption was obtained with the use of questionnaires and was confirmed by interview at each visit. The amount of milk consumed (glasses/d) was also determined from an interview-administered dairy-based food-frequency questionnaire at each time-point. At month 24, participants were asked not to include the calcium- and vitamin D fortified milk in their responses to this questionnaire. Statistical analysis Statistical analysis was conducted by using STATA statistical software (version 8.0; Stata Corp, College Station, TX). Baseline characteristics between the groups were compared by using independent t tests for continuous variables and chi-square tests for categorical variables. Pooled time series regression analysis for longitudinal data with random-effects models was used to analyze time, group, and interaction effects for all continuous variables (ie, anthropometry, physical activity, diet, and BMD) in the 109 men who completed the study. To compare the changes in BMD between the groups, results were analyzed after adjustment for baseline age, BMD, total calcium intake (or total calcium intake at month 42), and change in weight. The changes in BMD were expressed as the absolute and percentage changes from baseline or from the end of the 24-mo intervention. Betweengroup differences were calculated by subtracting the withingroup changes from baseline (or the follow-up) in the milk supplementation group from those in the control group. Generalized estimating equations (GEE modeling) with the logit link function (calcium and vitamin D supplementation use) and longitudinal ordinal regression (frequency of milk consumption) were used to test within-group changes and between-group differences in the change in each of these measures. All data are presented as means SDs or 95% CI unless stated otherwise. RESULTS The characteristics of the 109 men at baseline, at the end of the 2-y intervention (beginning of follow-up), and at the 18-mo follow-up are shown in Table 1. There were no differences in anthropometric measures, physical activity levels, or dietary habits between the 2 groups at baseline or at the end of the intervention (month 24) except that dietary calcium intakes were greater in the milk supplementation group than in the control group at both of these time-points; vitamin D and phosphorus intakes were also greater in the milk supplementation group than in the control group at month 24. This difference was due to the inclusion of the calcium- and vitamin D 3 fortified milk in the

3 RESIDUAL BENEFITS OF FORTIFIED MILK ON BMD IN MEN 773 TABLE 1 Age, anthropometric, physical activity, and dietary characteristics of the study participants at baseline and at the end of the intervention (month 24) and follow-up (month 42) for the milk supplementation and control groups 1 Characteristic and group Baseline (month 0) End of intervention (month 24) P for interaction (0 24 mo) End of follow-up (month 42) P for interaction (0 42 mo) Age (y) Milk Control Height (cm) Milk Control Weight (kg) Milk Control BMI (kg/m 2 ) Milk Control Weight-bearing exercise (h/wk) Milk Control Total energy intake (kj/d) Milk Control Protein (g) Milk Control Fat (g) Milk Control Protein (% of energy) Milk Control Fat (% of energy) Milk Control Carbohydrates (% of energy) Milk Control Dietary calcium (mg/d) Milk , Control Dietary vitamin D ( g/d) Milk , ,5 Control Phosphorus (mg/d) Milk , Control n 55 and 54 in milk supplementation and control groups, respectively. All dietary data (3-d food diaries) for the milk supplementation group at month 24 include fortified milk. Interaction terms represent the significance levels for the group-by-time interactions for the changes after 24 and 42 mo. 2 x SD (all such values). 3,4 Significant within-group change from month 24: 3 P 0.05, 4 P ,8,9 Significant within-group change from baseline (month 0): 5 P 0.05, 8 P 0.001, 9 P ,7 Significantly different from controls: 6 P 0.05, 7 P mo dietary analysis. During the follow-up period, total energy, protein (in g), dietary and total calcium, and vitamin D and phosphorus intakes decreased significantly from the month 24 values in the milk supplementation group (Table 1). The mean reduction in dietary calcium and vitamin D was 801 mg/d and 17.6 g/d, respectively. There were no changes in any of the dietary variables in the control group from month 24 to month 42. Similarly, at the end of the follow-up period, there were no significant differences between the milk supplementation and control groups with respect to any of the dietary variables. Physical activity levels remained unchanged in both groups throughout the study. Body weight decreased in the milk supplementation group during the follow-up (mean change: 1.2 kg; 95% CI, 0.07, 2.4 kg), but this change did not differ significantly from that in control subjects (mean change: 0.6 kg; 95% CI, 0.4, kg). There were no group time interactions for calcium or vitamin D supplement use or the frequency of milk consumption

4 774 DALY ET AL TABLE 2 Proportion of men by treatment group who used a calcium or vitamin D supplement (or both), total calcium and vitamin D intake (supplements plus diet), and the frequency of milk consumption at baseline and at the end of the intervention and follow-up periods Baseline (month 0) End of intervention (month 24) Follow-up (month 42) Characteristic Milk group (n 55) Control group (n 54) Milk group (n 55) Control group (n 54) P for interaction (0 24 mo) Milk group (n 55) Control group (n 54) P for interaction (0 42 mo) Calcium supplement use (%) 1 None mg/d mg/d mg/d Total calcium intake (mg/d) , , Vitamin D supplement use (%) 1 None IU/d IU/d IU/d Total vitamin D intake ( g/d) , Frequency of milk consumption (%) 9 Rarely or never glass/d glasses/d glasses/d The number of men who reported using calcium and vitamin D supplements increased significantly during the follow-up period (baseline to month 42) in both groups, P Total calcium and vitamin D intakes represent dietary and supplement intake. 3,4 Significantly different from controls: 3 P 0.05, 4 P ,8 Significant within-group change from baseline (month 0): 5 P 0.001, 8 P Nonsignificantly different from controls, P Significant within-group change from month 24, P One glass is equivalent to 225 ml. Frequency of milk consumption at month 24 in the milk supplementation group excludes the fortified milk used in this study. after 24 or 42 mo (Table 2). However, the number of men who reported using calcium and vitamin D supplements increased significantly from baseline to month 42 in both the milk supplementation and control groups (P 0.05 for both). However, at follow-up (month 42), there were no differences between the 2 groups in total calcium and vitamin D supplementation use (18.2% and 16.7%, respectively). Although dietary calcium decreased significantly (P 0.001) in the milk supplementation group from month 24 to month 42, there was a trend for total calcium intake (dietary plus supplemental) to be greater in the milk than in the control group at follow-up (P 0.10). Similarly, there was a greater trend for the men in the milk supplementation group than in the control group (69% and 51%, respectively; P 0.09) to have a total calcium intake at follow-up (month 42) greater than the current Australian estimated average requirement (EAR) of 840 mg/d for men y old (13). The EAR represents the daily calcium intake estimated to meet the requirements of 50% of Australian men in that age range. However, milk drinking habits did not differ significantly between the groups in the present study at any time during the intervention (Table 2). At the end of the intervention (month 24), however, the proportion of men in the milk supplementation group who reported regularly consuming milk tended to decrease (P 0.051), which is likely to be due to the exclusion during follow-up of the fortified milk used throughout the intervention; the men were asked during the interviewer-administered FFQ not to include the fortified milk as part of their postintervention daily milk consumption. At follow-up (month 42), 41% of all men reported that they consumed 1 glass of milk/d, whereas 45% reported consuming 1 2 or 2 glasses/d. Consistent with our previous report (8), there were no differences in baseline BMD at any skeletal site between the milk supplementation and control groups (Table 3). The mean adjusted between-group differences in the changes from baseline to the end of the intervention (month 24) and through follow-up (42 mo), and also in the duration of the follow-up (month 24 month 42), by treatment group for the 109 men who completed the study are reported in Table 4. The mean TABLE 3 Baseline bone mineral density in the fortified milk and control groups 1 Skeletal site Milk group Control group P Femoral neck Total hip Lumbar spine UD radius % radius n 55 and 54 in the fortified milk and control groups, respectively. UD, ultradistal. 2 x SD (all such values).

5 RESIDUAL BENEFITS OF FORTIFIED MILK ON BMD IN MEN 775 TABLE 4 Net adjusted mean absolute and percentage differences (and 95% CIs) in the change in bone mineral density (BMD) from baseline between the milk supplementation and control groups after the intervention and follow-up periods 1 Adjusted net differences (milk control group) (95% CI) BMD Intervention (0 24 mo) Follow-up mo 0 42 mo Femoral neck Absolute (0.007, 0.029) ( 0.016, 0.005) (0.000, 0.025) Percentage 1.8 (0.7, 3.0) 0.4 (, 0.6) 1.4 (0.1, 2.7) P Total hip Absolute ( 0.004, 0.019) ( 0.012, 0.007) ( 0.005, 0.018) Percentage 0.8 ( 0.4, 1.9) 0.2 ( 1.1, 0.7) 0.7 ( 0.4, 1.8) P Lumbar spine Absolute ( 0.002, 0.028) ( 0.018, 0.008) ( 0.019, 0.018) Percentage 0.9 ( 0.3, 2.2) 0.4 (, 0.7) 0.1 ( 1.6, 1.4) P UD radius Absolute (0.002, 0.010) ( 0.006, 0.005) (0.000, 0.009) Percentage (, 2.4) 0.1 ( 1.4, 1.2) 1.1 (0.0, 2.2) P % radius Absolute ( 0.003, 0.010) ( 0.010, 0.005) ( 0.005, 0.008) Percentage ( 0.3, 1.3) 0.4 ( 1.3, ) 0.2 ( 0.7, 1.0) P The adjusted net absolute and percentage differences represent the between-group differences (milk minus control group) in the changes in BMD after adjustment for baseline age, BMD, and change in weight. The inclusion of baseline or 42-mo total calcium intake did not alter the results. P values represent the significance of the group-by-time interactions for the changes after adjustment for the above covariates. unadjusted within-group changes are shown in Figure 1. Consistent with our previous report that included the full data set (n 149) (8), there was a significant between-group difference in the change in BMD relative to baseline after the 24-mo intervention in favor of the milk supplementation group at both the femoral neck (1.8%) and ultradistal radius (%). In contrast, the between-group difference at the total hip and the trend toward a difference at the lumbar spine in favor of the milk supplementation group in our previous study did not persist in this cohort [net adjusted percentage difference: total hip, 0.8% (P 0.17); lumbar spine, 0.9% (P 0.15)]. During the follow-up period (month 24 month 42), there was a small, nonsignificant decrease in BMD in both groups at the total hip and femoral neck, but there were no significant betweengroup differences in the changes in BMD at any skeletal site. Analysis of the mean changes from baseline between the groups showed that the net benefits of the fortified milk on femoral neck and ultradistal radius BMD after the intervention were sustained at the 18-mo follow-up. Similar results were also observed at the total hip, but the between-group difference remained nonsignificant at follow-up (net adjusted percentage difference, 0.7%; P 0.10). At the lumbar spine, the nonsignificant (0.9%) beneficial effect of the fortified milk on BMD was lost at follow-up ( 0.1%). There were no between-group differences in the change in BMD at the 33% radius at any time. These results remained unchanged after the inclusion of total calcium intake at follow-up (month 42) as a covariate. Furthermore, there was no significant effect of supplementation use on the changes in BMD at any skeletal site during the follow-up period in either group. DISCUSSION In this study of ambulatory community-dwelling older men who had previously participated in a 2-y RCT of calcium- and vitamin D 3 fortified milk, we found that the 1.8% and % net beneficial effects of the fortified milk on BMD at the clinically important femoral neck and ultradistal radius were sustained 18 mo after the end of the intervention. The 0.8% nonsignificant between-group differences at the total hip in favor of the milk supplementation group after the intervention also persisted at follow-up (0.7%), but there were no remaining supplementrelated benefits at the lumbar spine. It is likely that the residual skeletal benefits of the fortified milk in the men in this study were due to the maintenance of habitual calcium intakes at or above the current EAR (and recommended dietary intakes) for Australian men y old. Consistent with the findings from the present study, a recent follow-up study to a 2-y milk supplementation trial in postmenopausal Chinese women showed that the significant net beneficial effects of milk on lumbar spine and femoral neck BMD (1.2% and 1.7%, respectively) were maintained after a 21-mo follow-up (mean between-group difference: 1.3% and 1.9%, respectively) (10). In that study, the residual effects of the milk supplementation on BMD were attributed, at least partly, to the maintenance of a higher dietary calcium (and protein intake) in the milk supplementation group during the follow-up period. The mean total calcium intake of the women previously assigned to the milk supplementation group was 273 mg/d greater than that of the controls (768 and 495 mg/d, respectively). In contrast to these

6 776 DALY ET AL Percentage change from baseline (%) * A B Percentage change from baseline (%) C Intervention Follow-up Intervention Follow-up (mo) (mo) FIGURE 1. Mean ( SE) unadjusted percentage changes from baseline in femoral neck (A), total hip (B), lumbar spine (C), and ultradistal radius (D) bone mineral density (BMD) in 109 men who were randomly assigned to the calcium- and vitamin D 3 fortified milk (F) or control (E) group and then followed up after 18 mo with no supplementation. * Significant between-group difference from baseline (group time interaction) after adjustment for baseline age, BMD, total calcium intake (or total calcium intake at follow-up), and change in weight (P 0.05). * D findings, in the only previous calcium and vitamin D supplementation follow-up study to have included older men (it also included older women), Dawson-Hughes et al (9) reported that the supplement-related benefits to lumbar spine and femoral neck BMD were lost 2 y after the supplementation ended in the older men and women (aged 68 y), although there were some residual benefits to total-body BMD in the men. Dietary calcium intakes in the men in that study during the follow-up were 800 mg/d, which was considerably below the US National Academy of Sciences recommendation for dietary calcium of 1200 mg/d, and thus may have been inadequate to prevent bone loss. Contrary to these findings, the mean total calcium intake in the milk supplementation group at the end of the follow-up period in the present study was 1021 mg/d. Although this intake did not differ significantly from baseline values or from values in the control group at follow-up, which averaged 890 mg/d, it was greater than the current Australian EAR of 840 mg/d for men y old (13). Therefore, it would appear that maintaining a habitual calcium intake that exceeds the EAR for older men may be sufficient to prevent bone loss after withdrawal of supplementation. It is also possible that the provision of calcium in food products may result in a more sustained effect on BMD than do supplements. Partially supporting this possibility, the findings from a study in older women showed that those who obtain calcium primarily from the diet or from both diet and supplements had greater BMD than did those who obtain calcium primarily from supplements (14). There is some evidence to suggest that participation in nutrition-based interventions, BMD screening, an educational program designed to optimize bone health, or all 3 may lead to long-term behavioral changes with regard to increasing dietary intakes of calcium, vitamin D, or both (10, 15 18). In the present study, however, we found that dietary calcium intakes; the use of supplements with calcium, vitamin D, or both; and daily milk consumption did not differ significantly between the 2 groups 18 mo after the intervention. Although there was a trend for total calcium intake (combined diet and supplement use) to be greater in the milk supplementation group than in the control group at follow-up, dietary calcium intakes did not change significantly in the milk supplementation group from baseline to follow-up. Thus, it would appear that participation in a long-term foodbased intervention trial does not significantly influence the dietary behaviors of older men with respect to the intake of dietary calcium. Partially supporting these findings, the results from a 2-y follow-up study to a calcium tablet or milk powder supplementation trial showed that older women were more likely to continue voluntarily taking a tablet than to use a skim-milk powder supplement to maintain calcium intakes (19).

7 RESIDUAL BENEFITS OF FORTIFIED MILK ON BMD IN MEN 777 Several factors may explain the lack of a significant difference in total or dietary calcium intakes between the groups at followup. First, all of the men in the present study were informed of the study findings, and they received their individual BMD results after the completion of the 2-y intervention. A similar approach was adopted by Dawson-Hughes et al (9), who also reported that both the mean dietary calcium intakes and the use of calcium or vitamin D supplements were no greater in the treatment group than in the control group 2 y after calcium or vitamin D supplementation. Second, it is possible that the measures we used to monitor daily intakes of calcium and milk (3-d food diaries and FFQ) were not sensitive enough to detect any significant between-group differences that may have existed at follow-up. Third, dietary data were collected only at the end of the follow-up period, which may not provide an accurate estimate of the dietary habits of the men throughout the 18-mo follow-up period. Whereas the strength of this study lies in its long-term followup, there were 2 main limitations. First, only 73% of the men who completed the 2-y intervention returned for follow-up testing. However, the characteristics of these men were no different from those of the larger cohort of 149 men who completed the intervention, and the study remained adequately powered to detect significant between-group differences in the change in BMD. For the 2-y intervention, the observed power to detect a significant net beneficial effect of 1.8% and % at the femoral neck and ultradistal radius, respectively, in favor of the milk supplementation group in this cohort of 109 men was 95% and 82%, respectively. At the end of the follow-up period (month 42), we had 91% and 71% power for the observed 1.4% and 1.1% net differences at these 2 sites. Second, we have no information on the possible mechanism(s) that could explain the sustained effects on BMD in the milk supplementation group. Continued suppression of PTH could reduce the rate of bone loss, and that change could have been achieved by maintenance of a calcium intake equivalent to current recommended intakes in this group, but we did not measure PTH at follow-up. It has also been proposed that the additional protein associated with increased milk consumption may result in an increase in circulating concentrations of insulin-like growth factor-1 (20), an important growth factor known to stimulate bone formation, which may also enhance periosteal apposition. However, it is unlikely that this would explain the sustained benefits for BMD in the milk supplementation group, because we have previously reported no effect of the fortified milk on the quantitative computed tomography derived total bone cross-sectional area at the midfemur (21). In conclusion, the results from this study indicate that calciumand vitamin D 3 fortified milk may provide a sustained benefit for BMD in older men, which may help to prevent the development of osteoporosis later in life. Although the underlying mechanism contributing to these long-term beneficial skeletal effects remains to be determined, it is likely to be related to the maintenance of habitual calcium intakes above the current Australian recommended requirements for middle-aged and older men, which may assist in slowing bone loss. However, further longterm follow-up studies are needed to determine whether there is a threshold intake for dietary calcium or vitamin D or both above or below which any supplement-related skeletal gains may be maintained. The authors responsibilities were as follows RMD (principal investigator), SB, and CAN: study concept and design; RD and NP: acquisition of data; RD and CAN: analysis and interpretation of the data; RD: drafting of the manuscript; and CAN, SB, and NP: critical revision of the manuscript. None of the authors had a personal or financial conflict of interest. REFERENCES 1. Baeksgaard L, Andersen KP, Hyldstrup L. Calcium and vitamin D supplementation increases spinal BMD in healthy, postmenopausal women. Osteoporos Int 1998;8: Dawson Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997;337: Meier C, Woitge HW, Witte K, Lemmer B, Seibel MJ. Supplementation with oral vitamin D 3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial. J Bone Miner Res 2004;19: Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354: Chapuy MC, Pamphile R, Paris E, et al. Combined calcium and vitamin D 3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int 2002;13: Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D 3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992;327: Grados F, Brazier M, Kamel S, et al. Effects on bone mineral density of calcium and vitamin D supplementation in elderly women with vitamin D deficiency. Joint Bone Spine 2003;70: Daly RM, Brown M, Bass S, Kukuljan S, Nowson CA. Calcium and vitamin D 3 fortified milk reduces bone loss at clinically relevant skeletal sites in older men: a 2-year randomised controlled trial. J Bone Miner Res 2006;31: Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of withdrawal of calcium and vitamin D supplements on bone mass in elderly men and women. Am J Clin Nutr 2000;72: Ting GP, Tan SY, Chan SP, et al. A follow-up study on the effects of a milk supplement on bone mineral density of postmenopausal Chinese women in Malaysia. J Nutr Health Aging 2007;11: Devine A, Dick IM, Heal SJ, Criddle RA, Prince RL. A 4-year follow-up study of the effects of calcium supplementation on bone density in elderly postmenopausal women. Osteoporosis Int 1997;7: Harada ND, Chiu V, King AC, Stewart AL. An evaluation of three self-report physical activity instruments for older adults. Med Sci Sports Exerc 2001;33: National Health and Medical Research Council. Nutrient reference values for Australia and New Zealand including recommended dietary intakes. Canberra, Australia: Commonwealth of Australia and New Zealand Government, Napoli N, Thompson J, Civitelli R, Armamento-Villareal RC. Effects of dietary calcium compared with calcium supplements on estrogen metabolism and bone mineral density. Am J Clin Nutr 2007;85: Winzenberg T, Oldenburg B, Frendin S, De Wit L, Riley M, Jones G. The effect on behavior and bone mineral density of individualized bone mineral density feedback and educational interventions in premenopausal women: a randomized controlled trial. BMC Public Health 2006;6: Wong SY, Lau EM, Lau WW, Lynn HS. Is dietary counselling effective in increasing dietary calcium, protein and energy intake in patients with osteoporotic fractures? A randomized controlled clinical trial. J Hum Nutr Diet 2004;17: Cerulli J, Zeolla MM. Impact and feasibility of a community pharmacy bone mineral density screening and education program. J Am Pharm Assoc 2004;44: Tussing L, Chapman-Novakofski K. Osteoporosis prevention education: behavior theories and calcium intake. J Am Diet Assoc 2005;105: Devine A, Prince RL, Bell R. Nutritional effect of calcium supplementation by skim milk powder or calcium tablets on total nutrient intake in postmenopausal women. Am J Clin Nutr 1996;64: Heaney RP, McCarron DA, Dawson-Hughes B, et al. Dietary changes favorably affect bone remodeling in older adults. J Am Diet Assoc 1999;99: Daly RM, Bass S, Nowson C. Long-term effects of calcium-vitamin-d 3 fortified milk on bone geometry and strength in older men. Bone 2006; 39:

The Auckland calcium study: 5-year post-trial follow-up

The Auckland calcium study: 5-year post-trial follow-up Osteoporos Int (2014) 25:297 304 DOI 10.1007/s00198-013-2526-z ORIGINAL ARTICLE The Auckland calcium study: 5-year post-trial follow-up L. T. Radford & M. J. Bolland & B. Mason & A. Horne & G. D. Gamble

More information

Index. B BMC. See Bone mineral content BMD. See Bone mineral density Bone anabolic impact, Bone mass acquisition

Index. B BMC. See Bone mineral content BMD. See Bone mineral density Bone anabolic impact, Bone mass acquisition A Acid base balance dietary protein detrimental effects of, 19 Acid base balance bicarbonate effects, 176 in bone human studies, 174 mechanisms, 173 174 in muscle aging, 174 175 alkali supplementation

More information

9/26/2016. The Impact of Dietary Protein on the Musculoskeletal System. Research in dietary protein, musculoskeletal health and calcium economy

9/26/2016. The Impact of Dietary Protein on the Musculoskeletal System. Research in dietary protein, musculoskeletal health and calcium economy The Impact of Dietary Protein on the Musculoskeletal System Outline A. The musculoskeletal system and associated disorders Jessica D Bihuniak, PhD, RD Assistant Professor of Clinical Nutrition Department

More information

Additional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015. Dr.

Additional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015. Dr. Additional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015 Dr. Tessem Osteoporosis is a public health problem in all stages of life. Many

More information

Management of postmenopausal osteoporosis

Management of postmenopausal osteoporosis Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,

More information

Bone Metabolism in Postmenopausal Women Influenced by the Metabolic Syndrome

Bone Metabolism in Postmenopausal Women Influenced by the Metabolic Syndrome Bone Metabolism in Postmenopausal Women Influenced by the Metabolic Syndrome Thomas et al. Nutrition Journal (2015) 14:99 DOI 10.1186/s12937-015-0092-2 RESEARCH Open Access Acute effect of a supplemented

More information

Coordinator of Post Professional Programs Texas Woman's University 1

Coordinator of Post Professional Programs Texas Woman's University 1 OSTEOPOROSIS Update 2007-2008 April 26, 2008 How much of our BMD is under our control (vs. genetics)? 1 2 Genetic effects on bone loss: longitudinal twin study (Makovey, 2007) Peak BMD is under genetic

More information

Advances in Nutrition for Bone Health

Advances in Nutrition for Bone Health Advances in Nutrition for Bone Health IOF INTERNATIONAL OSTEOPOROSIS FOUNDATION Dominique D Pierroz, PhD, Science Manager, IOF www.iofbonehealth.org MEMBERSHIP STRUCTURE CSA Committee of Scientific Advisors

More information

Osteoporosis. Overview

Osteoporosis. Overview v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Bolland MJ, Grey A, Gamble GD, Reid IR. The

More information

V t i amin i n D a nd n d Calc l iu i m u : Rol o e l in i n Pr P eve v nt n io i n and n d Tr T eatment n of o Fr F actur u es and n d Fa F ll l s

V t i amin i n D a nd n d Calc l iu i m u : Rol o e l in i n Pr P eve v nt n io i n and n d Tr T eatment n of o Fr F actur u es and n d Fa F ll l s Vitamin D and Calcium: Role in Prevention and Treatment of Fractures and Falls Osteoporosis 21: New Insights In Research, Diagnosis, and Clinical Care Deborah Sellmeyer, MD Director, Johns Hopkins Metabolic

More information

Clinician s Guide to Prevention and Treatment of Osteoporosis

Clinician s Guide to Prevention and Treatment of Osteoporosis Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening

More information

Osteoporosis is a disease in which bones become fragile

Osteoporosis is a disease in which bones become fragile Preventing Osteoporosis the Bone Estrogen Strength Training Way by Linda B. Houtkooper, Ph.D., R.D., FACSM, Vanessa A. Stanford, M.S., R.D., CSCS, Lauve L. Metcalfe, M.S., FAWHP, Timothy G. Lohman, Ph.D.,

More information

BONE HEALTH BASICS. Promoting Healthy Bones: Sorting Out the Science. Learning Objectives. Guest Speaker

BONE HEALTH BASICS. Promoting Healthy Bones: Sorting Out the Science. Learning Objectives. Guest Speaker Copyright 11 by the Preventive Cardiovascular Nurses Association Promoting Healthy Bones: Sorting Out the Science Guest Speaker Robert P. Heaney, MD, FACP, FASN Professor and Professor of Medicine Creighton

More information

Osteoporosis - New Guidelines. Michelle Glass B.Sc. (Pharm) June 15, 2011

Osteoporosis - New Guidelines. Michelle Glass B.Sc. (Pharm) June 15, 2011 Osteoporosis - New Guidelines Michelle Glass B.Sc. (Pharm) June 15, 2011 Outline What is Osteoporosis? Who is at risk? What treatments are available? Role of the Pharmacy technician Definition of Osteoporosis

More information

NIH Public Access Author Manuscript Osteoporos Int. Author manuscript; available in PMC 2011 January 8.

NIH Public Access Author Manuscript Osteoporos Int. Author manuscript; available in PMC 2011 January 8. NIH Public Access Author Manuscript Published in final edited form as: Osteoporos Int. 2011 January ; 22(1): 345 349. doi:10.1007/s00198-010-1179-4. Does Dietary Protein Reduce Hip Fracture Risk in Elders?

More information

Emerging Areas Relating Vitamin D to Health

Emerging Areas Relating Vitamin D to Health ILSI SEA Region Vit D Conference, Australia, June 2012 (www.ilsi.org/sea Region) Emerging Areas Relating Vitamin D to Health Peter R Ebeling MD FRACP NorthWest Academic Centre and Dept Endocrinology The

More information

Benefits of Calcium and Vitamin D: Building and Maintaining Healthy Bones

Benefits of Calcium and Vitamin D: Building and Maintaining Healthy Bones Benefits of Calcium and Vitamin D: Building and Maintaining Healthy Bones Prepared by Annette Dickinson, Ph.D. Council for Responsible Nutrition June 2002 There is no question that a generous intake of

More information

Calcium and Vitamin D Supplementation is an Ineffective Strategy for the Prevention of Fractures in Older People

Calcium and Vitamin D Supplementation is an Ineffective Strategy for the Prevention of Fractures in Older People Calcium and Vitamin D Supplementation is an Ineffective Strategy for the Prevention of Fractures in Older People For the Motion: Professor Roger Francis, Institute for Ageing and Health, Newcastle University,

More information

Changes in Skeletal Systems over the Lifespan. Connie M. Weaver, Ph.D. Purdue University

Changes in Skeletal Systems over the Lifespan. Connie M. Weaver, Ph.D. Purdue University Changes in Skeletal Systems over the Lifespan Connie M. Weaver, Ph.D. Purdue University Disclosures Boards/Scientific Advisory Committees ILSI Showalter Pharmavite Grants NIH Dairy Research Institute Nestle

More information

Osteoporosis Screening and Treatment in Type 2 Diabetes

Osteoporosis Screening and Treatment in Type 2 Diabetes Osteoporosis Screening and Treatment in Type 2 Diabetes Ann Schwartz, PhD! Dept. of Epidemiology and Biostatistics! University of California San Francisco! October 2011! Presenter Disclosure Information

More information

CFDR Semi Annual Research Showcase May 1st, 2014

CFDR Semi Annual Research Showcase May 1st, 2014 CFDR Semi Annual Research Showcase May 1st, 2014 Source: Canada s Aging Population, Health Canada, 2002, p. 3 s The 2006 Census revealed that 4.3 million Canadians were > 65 y Almost 7% lived in health

More information

Challenging the Current Osteoporosis Guidelines. Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA

Challenging the Current Osteoporosis Guidelines. Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Challenging the Current Osteoporosis Guidelines Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Whom to screen Which test How to diagnose Whom to treat Benefits

More information

Nutritional concepts for the prevention and treatment of osteoporosis: what, for whom, when? Objectives

Nutritional concepts for the prevention and treatment of osteoporosis: what, for whom, when? Objectives Nutritional concepts for the prevention and treatment of osteoporosis: what, for whom, when? Bess Dawson-Hughes, MD Disclosures: Amgen, DSM, Nestle, Opko, Pfizer, Roche, Tricida Interrelationships of muscle

More information

DEVELOPMENT OF A RISK SCORING SYSTEM TO PREDICT A RISK OF OSTEOPOROTIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN

DEVELOPMENT OF A RISK SCORING SYSTEM TO PREDICT A RISK OF OSTEOPOROTIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN October 2-4, Liverpool, UK EURO SPINE 2013 DEVELOPMENT OF A RISK SCORING SYSTEM TO PREDICT A RISK OF OSTEOPOROTIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN D. Colangelo, L. A. Nasto, M. Mormando, E.

More information

Vitamin D and Calcium

Vitamin D and Calcium Vitamin D and Calcium American Association of Clinical Endocrinologists Marina Del Rey, CA September 15, 2018 Albert Shieh, MD MS Assistant Clinical Professor Department of Medicine Division of Endocrinology

More information

Vitamin D, Sunlight Exposure, and Bone Density in Elderly African American Females of Low Socioeconomic Status

Vitamin D, Sunlight Exposure, and Bone Density in Elderly African American Females of Low Socioeconomic Status Vol. 42, No. 1 47 Clinical Research and Methods Vitamin D, Sunlight Exposure, and Bone Density in Elderly African American Females of Low Socioeconomic Status Sally P. Weaver, PhD, MD; Cindy Passmore,

More information

MILK. Nutritious by nature. The science behind the health and nutritional impact of milk and dairy foods

MILK. Nutritious by nature. The science behind the health and nutritional impact of milk and dairy foods MILK Nutritious by nature The science behind the health and nutritional impact of milk and dairy foods Weight control Contrary to the popular perception that dairy foods are fattening, a growing body of

More information

Men and Osteoporosis So you think that it can t happen to you

Men and Osteoporosis So you think that it can t happen to you Men and Osteoporosis So you think that it can t happen to you Jonathan D. Adachi MD, FRCPC Alliance for Better Bone Health Chair in Rheumatology Professor, Department of Medicine Michael G. DeGroote School

More information

Body Mass Index as Predictor of Bone Mineral Density in Postmenopausal Women in India

Body Mass Index as Predictor of Bone Mineral Density in Postmenopausal Women in India International Journal of Public Health Science (IJPHS) Vol.3, No.4, December 2014, pp. 276 ~ 280 ISSN: 2252-8806 276 Body Mass Index as Predictor of Bone Mineral Density in Postmenopausal Women in India

More information

A systematic review of the effects of calcium supplementation on body weight

A systematic review of the effects of calcium supplementation on body weight British Journal of Nutrition (2006), 95, 1033 1038 q The Authors 2006 DOI: 10.1079/BJN20051727 Review Article A systematic review of the effects of calcium supplementation on body weight Rebecca Trowman

More information

Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC

Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with

More information

Building Bone Density-Research Issues

Building Bone Density-Research Issues Building Bone Density-Research Issues Helping to Regain Bone Density QUESTION 1 What are the symptoms of Osteoporosis? Who is at risk? Symptoms Bone Fractures Osteoporosis 1,500,000 fractures a year Kyphosis

More information

BAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008

BAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008 BAD TO THE BONE Peter Jones, Rheumatologist QE Health, Rotorua GP CME Conference Rotorua, June 2008 Agenda Osteoporosis in Men Vitamin D and Calcium Long-term treatment with Bisphosphonates Pathophysiology

More information

Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study

Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study Rheumatol Int (2006) 26: 427 431 DOI 10.1007/s00296-005-0004-4 ORIGINAL ARTICLE J. D. Ringe Æ H. Faber Æ P. Farahmand Æ A. Dorst Efficacy of risedronate in men with primary and secondary osteoporosis:

More information

Osteoporosis/Fracture Prevention

Osteoporosis/Fracture Prevention Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team

More information

B3D-MC-GHCY Clinical Study Report Synopsis Page 1Page GHCY Synopsis LY

B3D-MC-GHCY Clinical Study Report Synopsis Page 1Page GHCY Synopsis LY B3DMCGHCY Clinical Study Report Page 1Page 1 2. GHCY B3DMCGHCY Clinical ClinicalStudy StudyReport Report Page 2Page 2 Clinical Study Report : Study B3DMCGHCY Title of Study: The Effect of Teriparatide

More information

Inadequate Dietary Calcium and Vitamin D Intake in Patients with Osteoporotic Fracture

Inadequate Dietary Calcium and Vitamin D Intake in Patients with Osteoporotic Fracture J Bone Metab 2016;23:55-61 http://dx.doi.org/10.11005/jbm.2016.23.2.55 pissn 2287-6375 eissn 2287-7029 Original Article Inadequate Dietary Calcium and Vitamin D Intake in Patients with Osteoporotic Fracture

More information

Updates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1

Updates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1 Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in

More information

THE NEW ZEALAND MEDICAL JOURNAL

THE NEW ZEALAND MEDICAL JOURNAL THE NEW ZEALAND MEDICAL JOURNAL Vol 116 No 1179 ISSN 1175 8716 Efficacy of an oral, 10-day course of high-dose calciferol in correcting vitamin D deficiency Fiona Wu, Toni Staykova, Anne Horne, Judy Clearwater,

More information

Osteoporosis Update DR. SYLVIE OUELLETTE RHEUMATOLOGIST

Osteoporosis Update DR. SYLVIE OUELLETTE RHEUMATOLOGIST Osteoporosis Update DR. SYLVIE OUELLETTE RHEUMATOLOGIST Disclosures! Speaker programs! AbbVie, Amgen! Research! Amgen, Novartis! Education/ conference support! Amgen, Roche! Advisory Boards! AbbVie, Amgen,

More information

Vitamin D for the Prevention of Osteoporotic Fractures

Vitamin D for the Prevention of Osteoporotic Fractures TITLE: Vitamin D for the Prevention of Osteoporotic Fractures AUTHOR: Jeffrey A. Tice, MD Assistant Professor of Medicine Division of General Internal Medicine Department of Medicine University of California

More information

Shon E. Meek, M.D., Ph.D. Assistant Professor of Medicine

Shon E. Meek, M.D., Ph.D. Assistant Professor of Medicine Shon E. Meek, M.D., Ph.D. Assistant Professor of Medicine meek.shon@mayo.edu 2016 MFMER 3561772-1 Update on Vitamin D Shon Meek MD, PhD 20 th Annual Endocrine Update January 30-Feb 3, 2017 Disclosure Relevant

More information

OSTEOPOROSIS IS A disorder characterized by low

OSTEOPOROSIS IS A disorder characterized by low 0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(10):4916 4922 Printed in U.S.A. Copyright 2004 by The Endocrine Society doi: 10.1210/jc.2003-031985 The Effect of Calcium Supplementation

More information

Bone mineral density of patients attending a clinic in Dubai

Bone mineral density of patients attending a clinic in Dubai Bone mineral density of patients attending a clinic in Dubai Freshteh Hosseini Dana 1, Faisal Al-shammari 1, Asma usadiq 1, Maryam Nurudeen Abdurahman 1, Golshid Lotfizadeh 1*, Shatha Al-Sharbatti 2, Rizwana

More information

An audit of osteoporotic patients in an Australian general practice

An audit of osteoporotic patients in an Australian general practice professional Darren Parker An audit of osteoporotic patients in an Australian general practice Background Osteoporosis is a major contributor to morbidity and mortality in Australia, and is predicted to

More information

Evaluation of Bone Mineral Status in Adolescent Idiopathic Scoliosis

Evaluation of Bone Mineral Status in Adolescent Idiopathic Scoliosis Original Article Clinics in Orthopedic Surgery 2014;6:180-184 http://dx.doi.org/10.4055/cios.2014.6.2.180 Evaluation of Bone Mineral Status in Adolescent Idiopathic Scoliosis Babak Pourabbas Tahvildari,

More information

TREATMENT OF OSTEOPOROSIS

TREATMENT OF OSTEOPOROSIS TREATMENT OF OSTEOPOROSIS Summary Prevention is the key issue in the management of osteoporosis. HRT is the agent of choice for prevention of postmenopausal osteoporosis. Bisphosphonates and Calcitonin

More information

Effect of Precision Error on T-scores and the Diagnostic Classification of Bone Status

Effect of Precision Error on T-scores and the Diagnostic Classification of Bone Status Journal of Clinical Densitometry, vol. 10, no. 3, 239e243, 2007 Ó Copyright 2007 by The International Society for Clinical Densitometry 1094-6950/07/10:239e243/$32.00 DOI: 10.1016/j.jocd.2007.03.002 Original

More information

Prevalence of Comorbidities among HIV-positive patients in Taiwan

Prevalence of Comorbidities among HIV-positive patients in Taiwan Prevalence of Comorbidities among HIV-positive patients in Taiwan Chien-Ching Hung, MD, PhD Department of Internal Medicine National Taiwan University Hospital, Taipei, Taiwan % of participants Comorbidity

More information

Objectives: What is Osteoporosis 10/8/2015. Bone Health/ Osteoporosis: BASICS OF SCREENING, INTERPRETING, AND TREATING

Objectives: What is Osteoporosis 10/8/2015. Bone Health/ Osteoporosis: BASICS OF SCREENING, INTERPRETING, AND TREATING Bone Health/ Osteoporosis: BASICS OF SCREENING, INTERPRETING, AND TREATING TIFFANY PAUL, APN, CNP, CCD Objectives: Review the diagnosis of Osteoporosis Describe the basics of a bone density exam Identify

More information

The efficacy of calcium supplementation alone in elderly Thai women over a 2-year period: a randomized controlled trial

The efficacy of calcium supplementation alone in elderly Thai women over a 2-year period: a randomized controlled trial Osteoporos Int () 4:87 877 DOI.7/s98-87-5 ORIGINAL ARTICLE The efficacy of calcium supplementation alone in elderly Thai women over a -year period: a randomized controlled trial R. Rajatanavin & L. Chailurkit

More information

Osteoporosis: An Overview. Carolyn J. Crandall, MD, MS

Osteoporosis: An Overview. Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis

More information

Objectives. Polypharmacy Seminar. Causes of Polypharmacy. Polypharmacy 8/05/12. National Prescribing Curriculum Module

Objectives. Polypharmacy Seminar. Causes of Polypharmacy. Polypharmacy 8/05/12. National Prescribing Curriculum Module Polypharmacy Seminar Objectives On completion of this module you should be able to: state the major guiding principles in rational prescribing recognise, and substantiate, over-prescribing or inappropriate

More information

Interpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm

Interpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm Interpreting DEXA Scan and the New Fracture Risk Assessment Algorithm Prof. Samir Elbadawy *Osteoporosis affect 30%-40% of women in western countries and almost 15% of men after the age of 50 years. Osteoporosis

More information

1

1 www.osteoporosis.ca 1 2 Overview of the Presentation Osteoporosis: An Overview Bone Basics Diagnosis of Osteoporosis Drug Therapies Risk Reduction Living with Osteoporosis 3 What is Osteoporosis? Osteoporosis:

More information

TWO EXAMPLES OF A CHRONIC DISEASE PREVENTION WORKSHEET ADDRESSING PRIMARY, SECONDARY, AND TERTIARY APPROACHES TO OSTEOPOROSIS

TWO EXAMPLES OF A CHRONIC DISEASE PREVENTION WORKSHEET ADDRESSING PRIMARY, SECONDARY, AND TERTIARY APPROACHES TO OSTEOPOROSIS APPENDIX 17 B TWO EXAMPLES OF A CHRONIC DISEASE PREVENTION WORKSHEET ADDRESSING PRIMARY, SECONDARY, AND TERTIARY APPROACHES TO OSTEOPOROSIS Example 1 Target disease: Osteoporosis Target group: White females

More information

Prevention of fractures in older people with calcium and vitamin D

Prevention of fractures in older people with calcium and vitamin D Prevention of fractures in older people with calcium and vitamin D Citation: Nowson, Caryl A. 2010, Prevention of fractures in older people with calcium and vitamin D, Nutrients, vol. 2, no. 9, pp. 975-984.

More information

This study may not be disseminated, reproduced in whole or in part without the written permission of Roduve Healthcare Solutions.

This study may not be disseminated, reproduced in whole or in part without the written permission of Roduve Healthcare Solutions. This study may not be disseminated, reproduced in whole or in part without the written permission of Roduve Healthcare Solutions. A Randomized Controlled Trial for Roduve Healthcare Solutions on the Efficacy

More information

Calcium, Vitamin D and Bisphosphonates: Disclosures. Benefits, Risks and Drug Holiday. Calcium YES or NO? Calcium Bad News!!

Calcium, Vitamin D and Bisphosphonates: Disclosures. Benefits, Risks and Drug Holiday. Calcium YES or NO? Calcium Bad News!! Calcium, Vitamin D and Bisphosphonates: Benefits, Risks and Drug Holiday Disclosures I am disclosing financial relationships as follows: Global Advisory Boards: Amgen, Lilly, Merck, Novartis Research grants:

More information

Adrienne Forsyth. Food and nutrition for journey-based outdoor education

Adrienne Forsyth. Food and nutrition for journey-based outdoor education Adrienne Forsyth Food and nutrition for journey-based outdoor education A brief review of the literature revealed no peer-reviewed publications relating to nutrition requirements or evaluation in outdoor

More information

WHAT ARE AUSSIE KIDS

WHAT ARE AUSSIE KIDS WHAT ARE AUSSIE KIDS REALLY EATING? A DEEP DIVE INTO CONSUMPTION AMONG AUSTRALIAN CHILDREN & ADOLESCENTS A SECONDARY ANALYSIS OF THE 2011-12 NATIONAL NUTRITION AND PHYSICAL ACTIVITY SURVEY INFORMATION

More information

Annie WC Kung, Keith DK Luk, LW Chu, and Peter KY Chiu

Annie WC Kung, Keith DK Luk, LW Chu, and Peter KY Chiu Age-related osteoporosis in Chinese: an evaluation of the response of intestinal calcium absorption and calcitropic hormones to dietary calcium deprivation 1 3 Annie WC Kung, Keith DK Luk, LW Chu, and

More information

Calcium Nephrolithiasis and Bone Health. Noah S. Schenkman, MD

Calcium Nephrolithiasis and Bone Health. Noah S. Schenkman, MD Calcium Nephrolithiasis and Bone Health Noah S. Schenkman, MD Associate Professor of Urology and Residency Program Director, University of Virginia Health System; Charlottesville, Virginia Objectives:

More information

MEDICAL POLICY EFFECTIVE DATE: 08/21/14 REVISED DATE: 04/16/15, 06/16/16, 07/20/17 SUBJECT: SCREENING FOR VITAMIN D DEFICIENCY

MEDICAL POLICY EFFECTIVE DATE: 08/21/14 REVISED DATE: 04/16/15, 06/16/16, 07/20/17 SUBJECT: SCREENING FOR VITAMIN D DEFICIENCY MEDICAL POLICY SUBJECT: SCREENING FOR VITAMIN D DEFICIENCY A nonprofit independent licensee of the BlueCross BlueShield Association PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not

More information

Prevalence Of Vitamin D Inadequacy In Peri And Postmenopausal Women Presented At Dow University Hospital, Ojha Campus. A Cross Sectional Study

Prevalence Of Vitamin D Inadequacy In Peri And Postmenopausal Women Presented At Dow University Hospital, Ojha Campus. A Cross Sectional Study ISPUB.COM The Internet Journal of Nutrition and Wellness Volume 12 Number 1 Prevalence Of Vitamin D Inadequacy In Peri And Postmenopausal Women Presented At Dow University S Shukar-ud-din, R Tabassum,

More information

Chapter 39: Exercise prescription in those with osteoporosis

Chapter 39: Exercise prescription in those with osteoporosis Chapter 39: Exercise prescription in those with osteoporosis American College of Sports Medicine. (2010). ACSM's resource manual for guidelines for exercise testing and prescription (6th ed.). New York:

More information

The Bone Wellness Centre - Specialists in Dexa Scanning 855 Broadview Avenue Suite # 305 Toronto, Ontario M4K 3Z1

The Bone Wellness Centre - Specialists in Dexa Scanning 855 Broadview Avenue Suite # 305 Toronto, Ontario M4K 3Z1 Birth Date: 24.7 years Height / Weight: 8.0 cm 79.0 kg Sex / Ethnic: Male Patient ID: Total Body Tissue Quantitation Composition Reference: Total Tissue 40% 30% 20% 0% 20 30 40 50 60 70 80 90 00 Centile

More information

Prevention of falls and fractures

Prevention of falls and fractures ILSI SEA Region - Optimum Health & Nutrition for our Ageing populaiton. Australia - October 2012. www.ilsi.org/sea_region Prevention of falls and fractures http://www.narowing.org/men/brian%20best%20balance.jpg

More information

Oral Alendronate Vs. Three-Monthly Iv Ibandronate In The Treatment Of Postmenopausal Osteoporosis

Oral Alendronate Vs. Three-Monthly Iv Ibandronate In The Treatment Of Postmenopausal Osteoporosis Oral Alendronate Vs. Three-Monthly Iv Ibandronate In The Treatment Of Postmenopausal Osteoporosis Miriam Silverberg A. Study Purpose and Rationale More than 70% of fractures in people after the age of

More information

Dr Seeta Durvasula.

Dr Seeta Durvasula. Dr Seeta Durvasula seeta.durvasula@sydney.edu.au 1 Avoid sun skin cancer risk Australia has highest rates of skin cancer in the world Epidemic of Vitamin D deficiency Lack of Vitamin D increases risk of

More information

The Relationship between Prevalence of Osteoporosis and Proportion of Daily Protein Intake

The Relationship between Prevalence of Osteoporosis and Proportion of Daily Protein Intake Korean J Fam Med. 2013;34:43-48 http://dx.doi.org/10.4082/kjfm.2013.34.1.43 The Relationship between Prevalence of Osteoporosis and Proportion of Daily Protein Intake Original Article Junga Kim, Byungsung

More information

nogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK

nogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,

More information

Vitamin K intake and bone mineral density in women and men 1 4

Vitamin K intake and bone mineral density in women and men 1 4 Vitamin K intake and bone mineral density in women and men 1 4 Sarah L Booth, Kerry E Broe, David R Gagnon, Katherine L Tucker, Marian T Hannan, Robert R McLean, Bess Dawson-Hughes, Peter WF Wilson, L

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage

More information

The relationship between daily calcium intake and bone mineral density in men with prostate cancer

The relationship between daily calcium intake and bone mineral density in men with prostate cancer Original Article DAILY CALCIUM INTAKE AND BONE MINERAL DENSITY IN PROSTATE CANCER PLANAS ET AL. The relationship between daily calcium intake and bone mineral density in men with prostate cancer Jacques

More information

Current Issues in Osteoporosis

Current Issues in Osteoporosis Current Issues in Osteoporosis California AACE 18TH Annual Meeting & Symposium Marina del Rey, CA September 15, 2018 Michael R. McClung, MD, FACP,FACE Director, Oregon Osteoporosis Center Portland, Oregon,

More information

JOURNAL OF INTERNATIONAL ACADEMIC RESEARCH FOR MULTIDISCIPLINARY Impact Factor 1.393, ISSN: , Volume 2, Issue 7, August 2014

JOURNAL OF INTERNATIONAL ACADEMIC RESEARCH FOR MULTIDISCIPLINARY Impact Factor 1.393, ISSN: , Volume 2, Issue 7, August 2014 HYPOVITAMINOSIS D IN INDIAN FEMALES WITH POSTMENOPAUSAL OSTEOPOROSIS DR. SHAH WALIULLAH 1 DR. VINEET SHARMA 2 DR. R N SRIVASTAVA 3 DR. YASHODHARA PRADEEP 4 DR. A A MAHDI 5 DR. SANTOSH KUMAR 6 1 Research

More information

Bone Mass Measurement BONE MASS MEASUREMENT HS-042. Policy Number: HS-042. Original Effective Date: 8/25/2008

Bone Mass Measurement BONE MASS MEASUREMENT HS-042. Policy Number: HS-042. Original Effective Date: 8/25/2008 Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,

More information

Product: Denosumab (AMG 162) Clinical Study Report: month Primary Analysis Date: 21 November 2016 Page 1

Product: Denosumab (AMG 162) Clinical Study Report: month Primary Analysis Date: 21 November 2016 Page 1 Date: 21 November 2016 Page 1 2. SYNOPSIS Name of Sponsor: Amgen Inc., Thousand Oaks, CA, USA Name of Finished Product: Prolia Name of Active Ingredient: denosumab Title of Study: Randomized, Double-blind,

More information

High Dietary Sodium Intake Assessed by 24-hour Urine Specimen Increase Urinary Calcium Excretion and Bone Resorption Marker

High Dietary Sodium Intake Assessed by 24-hour Urine Specimen Increase Urinary Calcium Excretion and Bone Resorption Marker J Bone Metab 214;21:189-194 http://dx.doi.org/1.115/jbm.214.21.3.189 pissn 2287-6375 eissn 2287-729 Original Article High Dietary Sodium Intake Assessed by 24-hour Urine Specimen Increase Urinary Calcium

More information

Who should receive calcium and vitamin D supplementation?

Who should receive calcium and vitamin D supplementation? Age and Ageing Advance Access published August 8, 2012 Age and Ageing 2012; 0: 1 5 The Author 2012. Published by Oxford University Press on behalf of the British Geriatrics Society. doi: 10.1093/ageing/afs094

More information

Vitamin D. Vitamin functioning as hormone. Todd A Fearer, MD FACP

Vitamin D. Vitamin functioning as hormone. Todd A Fearer, MD FACP Vitamin D Vitamin functioning as hormone Todd A Fearer, MD FACP Vitamin overview Vitamins are organic compounds that are essential in small amounts for normal metabolism They are different from minerals

More information

Closing the Care Gap in Osteoporosis ICE Conference 2015

Closing the Care Gap in Osteoporosis ICE Conference 2015 Closing the Care Gap in Osteoporosis ICE Conference 2015 Pat McCarthy-Briggs RD, MHEd Thank You! What is osteoporosis? a systemic skeletal disease characterized by low bone mass and microarchitectural

More information

denosumab (Prolia ) Policy # Original Effective Date: 07/21/2011 Current Effective Date: 04/19/2017

denosumab (Prolia ) Policy # Original Effective Date: 07/21/2011 Current Effective Date: 04/19/2017 Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

Based on review of available data, the Company may consider the use of denosumab (Prolia) for the

Based on review of available data, the Company may consider the use of denosumab (Prolia) for the Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

The health economics of calcium and vitamin D3 for the prevention of osteoporotic hip fractures in Sweden Willis M S

The health economics of calcium and vitamin D3 for the prevention of osteoporotic hip fractures in Sweden Willis M S The health economics of calcium and vitamin D3 for the prevention of osteoporotic hip fractures in Sweden Willis M S Record Status This is a critical abstract of an economic evaluation that meets the criteria

More information

Vitamin D Status of an Outpatient Clinic Population

Vitamin D Status of an Outpatient Clinic Population Calcif Tissue Int (2001) 69:263 267 DOI: 10.1007/s002230010054 2001 Springer-Verlag New York Inc. Vitamin D Status of an Outpatient Clinic Population L. Margiloff, 1 S. S. Harris, 2 S. Lee, 3 R. Lechan,

More information

Page 1. New Developments in Osteoporosis. What s New in Osteoporosis

Page 1. New Developments in Osteoporosis. What s New in Osteoporosis New Developments in Osteoporosis Eliseo J. Pérez-Stable MD Professor of Medicine Division of General Internal Medicine Department of Medicine July 4, 2013 Declaration of full disclosure: No conflict of

More information

Dietary Protein and Bone Health Emphasis: Animal Protein

Dietary Protein and Bone Health Emphasis: Animal Protein USDA-ARS Human Nutrition Research Centers Dietary Protein and Bone Health Emphasis: Animal Protein Z.K. (Fariba) Roughead, PhD, RD Research Nutritionist USDA-ARS Grand Forks Human Nutrition Research Center

More information

Long-term effects of nutrient intervention on markers of bone remodeling and calciotropic hormones in late-postmenopausal women 1 4

Long-term effects of nutrient intervention on markers of bone remodeling and calciotropic hormones in late-postmenopausal women 1 4 Long-term effects of nutrient intervention on markers of bone remodeling and calciotropic hormones in late-postmenopausal women 1 4 Christopher Jensen, Leah Holloway, Gladys Block, Gene Spiller, Ginny

More information

No effect of exercise on insulin-like growth factor (IGF)-1, insulin and glucose in young women participating in a 16-week randomized controlled trial

No effect of exercise on insulin-like growth factor (IGF)-1, insulin and glucose in young women participating in a 16-week randomized controlled trial University of North Florida UNF Digital Commons Nutrition and Dietetics Faculty Publications Department of Nutrition and Dietetics 11-2010 No effect of exercise on insulin-like growth factor (IGF)-1, insulin

More information

The Bone Wellness Centre - Specialists in DEXA Scanning 855 Broadview Avenue Suite # 305 Toronto, Ontario M4K 3Z1

The Bone Wellness Centre - Specialists in DEXA Scanning 855 Broadview Avenue Suite # 305 Toronto, Ontario M4K 3Z1 Birth Date: 40.2 years Height / Weight: 158.0 cm 52.0 kg Sex / Ethnic: Female Patient ID: Total Body Tissue Quantitation Composition Reference: Total Tissue 50% 40% 30% 20% 20 30 40 50 60 70 80 90 100

More information

JBMR. Serum 25-hydroxyvitamin D [25(OH)D] concentration may or

JBMR. Serum 25-hydroxyvitamin D [25(OH)D] concentration may or ORIGINAL ARTICLE JBMR Impact of Calcium and Vitamin D Insufficiencies on Serum Parathyroid Hormone and Bone Mineral Density: Analysis of the Fourth and Fifth Korea National Health and Nutrition Examination

More information

ASSOCIATION BETWEEN DIETARY CALCIUM INTAKES AND WEIGHT LOSS

ASSOCIATION BETWEEN DIETARY CALCIUM INTAKES AND WEIGHT LOSS ASSOCIATION BETWEEN DIETARY CALCIUM INTAKES AND WEIGHT LOSS Presented By: Prof. Mohamed S. Ismail Institution Current: Dept. Clin. Nutr. Univ. Of Dammam, KSA Permanent: Nutr. Food Sci. Menoufia Univ. Egypt

More information

Name of Active Ingredient: Fully human monoclonal antibody to receptor activator for nuclear factor-κb ligand

Name of Active Ingredient: Fully human monoclonal antibody to receptor activator for nuclear factor-κb ligand Page 2 of 1765 2. SYNOPSIS Name of Sponsor: Amgen Inc. Name of Finished Product: Denosumab (AMG 162) Name of Active Ingredient: Fully human monoclonal antibody to receptor activator for nuclear factor-κb

More information

Research Article Repeatability of a Short Food Frequency Questionnaire to Assess Calcium Intake in Older Australians

Research Article Repeatability of a Short Food Frequency Questionnaire to Assess Calcium Intake in Older Australians SAGE-Hindawi Access to Research Journal of Aging Research Volume 2010, Article ID 905056, 5 pages doi:10.4061/2010/905056 Research Article Repeatability of a Short Food Frequency Questionnaire to Assess

More information

Calcium supplementation and bone mineral accretion in adolescent girls: an 18-mo randomized controlled trial with 2-y follow-up 1 3

Calcium supplementation and bone mineral accretion in adolescent girls: an 18-mo randomized controlled trial with 2-y follow-up 1 3 Calcium supplementation and bone mineral accretion in adolescent girls: an 18-mo randomized controlled trial with 2-y follow-up 1 3 Helen L Lambert, Richard Eastell, Kavita Karnik, Jean M Russell, and

More information

Page 1. Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? What s New in Osteoporosis

Page 1. Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? What s New in Osteoporosis Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco What s

More information

OSTEOPOROSIS: PREVENTION AND MANAGEMENT

OSTEOPOROSIS: PREVENTION AND MANAGEMENT OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring

More information